The Conversation (0)
NEW YORK–(BUSINESS WIRE)–Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company’s board of directors. In 2006 Dr. Ulrich co-founded Calistoga Pharmaceuticals, which was acquired by Gilead Sciences (NASDAQ:GILD) in 2011 in a transaction …
NEW YORK–(BUSINESS WIRE)–Remedy Pharmaceuticals, a privately-held pharmaceutical company focused
on bringing life-saving hospital-based treatment to people affected by
central nervous system (CNS) related edema, today announced that Roger
Ulrich has joined the company’s board of directors.
In 2006 Dr. Ulrich co-founded Calistoga Pharmaceuticals, which was
acquired by Gilead Sciences (NASDAQ:GILD) in 2011 in a transaction
valued at up to $600 million. Dr. Ulrich left Gilead in 2012 to help
build Acerta Pharma as a member of the Board and as acting Chief
Scientific Officer. In February of this year, AstraZeneca (NYSE:AZN)
acquired a 55% share of Acerta Pharma for $4 billion with an option to
purchase the remainder of the company for $3 billion.
Dr. Ulrich has many years of successful drug discovery and development
experience. Prior to Acerta and Calistoga, Dr. Ulrich was senior
scientific director with Merck Research Laboratories-Rosetta
Inpharmatics (NYSE:MRK). Prior to Merck, Dr. Ulrich held various
scientific and leadership positions within the pharmaceutical industry
including Abbott Laboratories (now AbbVie, NYSE:ABBV), Pharmacia-Upjohn
and The Upjohn Company, now part of Pfizer (NYSE:PFE). Prior to his
pharmaceutical industry career, he worked at West Virginia and Michigan
State Universities, and at Argonne National Laboratories. Dr. Ulrich has
authored more than 125 publications and continues to serve on scientific
and clinical advisory boards for industry, academia and government.
Dr. Ulrich received his B.A. in biology/chemistry and his M.A. in
biomedical sciences from Western Michigan University. He received a
Ph.D. in cellular and molecular biology from West Virginia University,
and is a fellow of the Academy of Toxicological Sciences.
“We are honored to have Roger join our Board,” said David Geliebter,
Executive Chairman of Remedy Pharmaceuticals. “He has achieved
extraordinary success helping advance medicine, and is sure to be a
tremendous asset as we move forward in achieving our mission of helping
people afflicted with CNS-related edema to not only survive, but live
life to the fullest.”
“I am very excited to join the Board of Remedy, said Roger Ulrich. “The
company’s underlying science is transformative and I look forward to
working with the board and the team to help shape what I’m certain to be
its bright future.”
ABOUT CIRARA
CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels,
which are upregulated following ischemia and trauma. Opening of these
channels can lead to edema, midline shift, increased intracranial
pressure and brain herniation, culminating in permanent disability or
death. Sur1-Trpm4 channels were discovered by University of Maryland
neurosurgeon Dr. J. Marc Simard, scientific founder and board member of
Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at
the bedside or even in an ambulance. CIRARA uses our proprietary,
patented MPD™ technology. CIRARA is an investigational drug and is not
approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage
pharmaceutical company focused on developing and bringing lifesaving
treatment to people affected by acute central nervous system (CNS) edema
– including large hemispheric infarction, subarachnoid hemorrhage, and
contusional traumatic brain injury, as well as other ischemic injuries
and neurological disorders.